- Home
- ADVM vs SOL Comparison
ADVM vs SOL Comparison
Compare ADVM & SOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- SOL
- Stock Information
- Founded
- ADVM 2006
- SOL 2005
- Country
- ADVM United States
- SOL United States
- Employees
- ADVM N/A
- SOL N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- SOL Semiconductors
- Sector
- ADVM Health Care
- SOL Technology
- Exchange
- ADVM Nasdaq
- SOL Nasdaq
- Market Cap
- ADVM 119.6M
- SOL 97.4M
- IPO Year
- ADVM 2014
- SOL 2008
- Fundamental
- Price
- ADVM $4.74
- SOL $2.10
- Analyst Decision
- ADVM Strong Buy
- SOL Buy
- Analyst Count
- ADVM 6
- SOL 3
- Target Price
- ADVM $27.83
- SOL $3.83
- AVG Volume (30 Days)
- ADVM 226.5K
- SOL 229.4K
- Earning Date
- ADVM 11-04-2024
- SOL 11-14-2024
- Dividend Yield
- ADVM N/A
- SOL N/A
- EPS Growth
- ADVM N/A
- SOL N/A
- EPS
- ADVM N/A
- SOL N/A
- Revenue
- ADVM $1,000,000.00
- SOL $102,489,000.00
- Revenue This Year
- ADVM N/A
- SOL N/A
- Revenue Next Year
- ADVM $1,342.84
- SOL $46.42
- P/E Ratio
- ADVM N/A
- SOL N/A
- Revenue Growth
- ADVM N/A
- SOL 25.98
- 52 Week Low
- ADVM $4.59
- SOL $1.41
- 52 Week High
- ADVM $29.70
- SOL $3.00
- Technical
- Relative Strength Index (RSI)
- ADVM 26.02
- SOL 57.76
- Support Level
- ADVM $4.59
- SOL $1.75
- Resistance Level
- ADVM $4.89
- SOL $1.98
- Average True Range (ATR)
- ADVM 0.31
- SOL 0.13
- MACD
- ADVM -0.06
- SOL 0.04
- Stochastic Oscillator
- ADVM 9.80
- SOL 97.83
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.